How to apply HCC prediction models to practice?
|
|
- Opal Barker
- 5 years ago
- Views:
Transcription
1 How to apply HCC prediction models to practice? Department of Internal Medicine, Keimyung University School of Medicine Woo Jin Chung
2 HCC prediction models 독특하게간세포암환자들의생존은암의진행상태뿐아니라기저간기능의중증정도에영향을받는특성이있다. 임상에서쉽게적용이가능한유용한예측모델에관한요구가있고이에대해다양한예측모델들이보고되고있다. 이러한예측모델들은 1) 사용되는예측인자들이언제나재현이가능해야하며, 2) 쉽게임상에서적용이가능하며, 3) 임상적으로의미있는결과를유출할수있어야한다. Objective parameters Subjective parameters Parameters readily available Prospectively designed Validated Prediction models?????
3 HCC prediction models: HCC Risk Laboratory based algorithm to predict HCC 2014 Gastroenterology HCC risk prediction scores 2014 Gut ADRESS-HCC Risk model 2014 Cancer Clinical scoring system 2014 PLoS ONE Transient elastography based risk estimation 2014 Oncotargets Ther Prediction models risk score 2013 Hepatology Prediction model by Japanese PHC 2012 Preventive Medicine Data mining model 2012 J Hepatol
4 HCC prediction models: Survival Criteria specific long-term survival prediction model after LT 2015 Scientific reports DCE-MRI kinetic parameters as prognostic biomarkers 2015 Acad Radiol Prognostic model based on Bayesian Network after hepatectomy 2015 PLoS ONE K-MESIAH 2015 PLoS ONE Score model for survival after LT 2015 HBPD int Artificial Neural Network model 2012 PLoS ONE MESIAH 2012 Hepatology
5 HCC prediction models: Prognosis Optimal cutoff of serum afp PLoS ONE Predicting prognosis after curative surgery 2009 BMC Cancer HCC prediction models: Metastasis microrna-based prediction model 2015 Oncotarget Clinicopathological model to predict bone metastasis 2011 J Cancer Res Clin Oncol
6 HCC prediction models: Microvascular invasion Preoperative estimation of microvascular invasion risk 2015 JAMA Surg Preoperative prediction of tumor grade and microvascular invasion 2010 J Hepatol HCC prediction models: Disease-free survival Prediction by gene expression profiling 2013 Ann Surg Oncol
7 HCC prediction models: Mortality Mortality risk after LT 2012 Surgery MELD 2003 Gastroenterology HCC prediction models: Recurrence Platelet count before therapy WJG Preoperative scoring model after resection or LT 2015 HBPD Int Genomic predictor models 2014 PLoS Medicine
8 Laboratory based Algorithm to Predict HCC: In patients with Hepatitis C and LC 50대 70대 N=11,721 At any given AFP value, low numbers of platelets and ALT and older age were associated with increased risk of HCC, whereas high levels of ALT and normal/high numbers of platelets were associated with low risk for HCC. For example, the probabilities of HCC, based only on 20 ng/ml and 120 ng/ml AFP, were 3.5% and 11.4%, respectively. However patients with the same AFP values (20 ng/ml and 120 ng/ml) who were 70y old, with ALT levels of 40 IU/ml and platelet counts of 100,000, had probabilities of developing HCC of 8.1% and 29.0%, respectively. El-Serag HB et al, Gastroenterology 2014
9 ADRESS-HCC Risk Model: Risk Prediction of HCC in Patients with Cirrhosis N=34,932 An ADRESS-HCC score of 4.67 identified those whose risk of HCC was 1.5% per year. No patient with an ADRESS-HCC score of <2.15 (80 patients) developed HCC during the follow-up period. Conclusions: The ADRESS-HCC risk model is a useful tool for predicting the 1-year risk of HCC among patients with cirrhosis. ADRESS: age, diabetes, etiology of cirrhosis, sex, and severity Flemming JA, Norah Terrault et al, Cancer 2014
10 Clinical Score System for Predict Risk of HCC: Asymptomatic anti-hcv(+) from REVEAL HCV cohort N=975 & 572 The predicted risks for HCC were estimated by sum of risk scores by the equation: P 0 was the baseline disease free probability, βi was the regression coefficient for the ith variables (Xi), Mi denoted the mean level of Xi 1. all anti-hcv seropositives (risk score <13 for low-risk, for medium-risk, 19 for high-risk group) 2. anti-hcv seropositives with detectable HCV RNA (risk score <9 for low-risk, 9 15 for medium-risk, 15 for high-risk group). Conclusions: Scoring systems for predicting HCC risk of HCVinfected patients had good validity and discrimination capability, which may triage patients for alternative management strategies. Lee MH, Chen CJ et al, Hepatology > Lee MH, Chen CJ et al, PLoS ONE 2014
11 Transient elastography based risk estimation of HCC: Predictive model for HBV related occurrence of HCC N=1,250 3-year probability of HCC occurrence The predicted risk of occurrence of HCC calibrated well with the observed risk, with a correlation coefficient of (P<0.001). Conclusions: This novel model accurately estimated the risk of HCC occurrence in patients with chronic hepatitis B Kim DY, Han KH et al, Oncotargets and Ther 2014
12 Prediction Model for 10yr Risk of HCC: In middle aged Japanese by JPHC based Prospective Study Cohort N=17,654 Those subjects with total scores of 17 or more under this system (score range: 1 to 19) had an estimated 10-year HCC risk of over 90%; those with 4 points or less had an estimated risk of less than 0.1%. Michikawa T, Manami Inoue et al, Preventive Medicine 2012
13 Data Mining Model to Identify Risk of HCC: To identify patients at high risk for HCC in CHC HCC 누적발생 N=1,003 IFN 치료로 SVR 후 HCC 누적발생 High -> Intermediate -> Low risk HCC risk group / % 5 year 10 year 누적발생 SVR (+/-) 누적발생 High and intermediate risk 11.6% 4.5 vs 9.5% 24.5% Low risk 1.0% 0.9 vs 1.8% 4.8% Conclusions: The model allows physicians to identify patients requiring HCC surveillance and those who benefit from IFN therapy to prevent HCC. Kurosaki M, Namiki Izumi et al, J Hepatol 2012
14 AATH Model for Prediction of Survival : Dynamic contrast-enhanced MRI kinetic Parameters as Prognostic Biomarkers N=20 Arterial flow fraction Fractional interstitial volume The adiabatic approximation to the tissue homogenicity (AATH) model-derived PS was an effective prognostic biomarker for both 1YS and OS. Permeability-surface area product Lee SH, hiroyuki Yoshida et al, Academic Radiology 2015;22(11):
15 MESIAH: Model to Estimate Survival in Ambulatory patients with HCC N=477 & 904 Risk score 25, 75 th percentile 기준으로 Tier 1, 2, 3 로분류 Conclusions: A new model to predict survival of HCC patients based on objective parameters provides refined prognostication and supplements the BCLC classification. Yang JD, W. Ray Kim et al, Hepatology 2012
16 K-MESIAH: Korean version of Model to Estimate Survival in Ambulatory patients with HCC N=1,969 Risk probability Conclusions: A survival prediction model for Korean HCC patients was developed and validated to have a high level of performance. This K-MESIAH may be more useful in clinical practice and personalized care in a hepatitis B virus endemic area. Nam BH, Park JW et al, PLoS ONE 2015
17 Score Model for Survival after LT: A score model for predicting post-lt survival in HBV LC related HCC recipients The score model was as follows: N= (Child-Pugh score) (positive HBV DNA detection time) (number of tumor nodules) (max diameter of tumor nodules) lnafp (tumor differentiation grade). AUROC The receiver operating characteristic curve analysis showed that the area under the curve of the scoring model for predicting the post-lt survival was The cut-off value was 1.27, which was associated with a sensitivity of 72.5% and a specificity of 90.7%, respectively. Wang LY et al, HBPD Int 2015;14:43-49
18 MELD: Model for End-Stage Liver Disease MELD Score = 10 * ((0.957 * ln(creatinine)) + (0.378 * ln(bilirubin)) + (1.12 * ln(inr))) MELD calculator Weisner R, Ray Kim et al Gastroenterology 2003
19 Predicting Prognosis with Common Clinicopathologic Parameters: In HCC patients after curative surgery N=572 Survival Disease free Survival 6 common clinicopathologic parameters (tumor size, number of tumor nodules, tumor stage, venous infiltration status, and serum α-fetoprotein and total albumin levels) that were significantly associated with the overall HCC survival and disease-free survival (time to recurrence). Hao K, Luk JM et al, BMC Cancer 2009
20 Prediction model for LN Metastasis: A microrna-based prediction model N=192 Five LNM associated predictive factors: vascular invasion, BCLC stage, mir-145, mir-31, and mir-92a. The cutoff value 4 was used to distinguish high and low- risk groups. The model sensitivity and specificity was 69.6 and 80.2%. And the area under the curve (AUC) for the mirna-based prognostic model was The 5-year positive and negative predictive values of the model in the validation cohort were 30.3 and 95.5 %, respectively. Cox regression analysis revealed that the LNM hazard ratio of the high-risk versus low-risk groups was (95 % CI, ; P < 0.001) in the validation cohort. Conclusion, the mirna-based model is reliable and accurate for the early prediction of LNM in patients with HCC. Zhang L, Xiang ZL et al, Oncotarget 2015
21 Clinocopathological Model to Predict Bone Metastasis: N=179 A cutoff value of 9.4 best discriminated BM risk and was able to exclude future BM development with high accuracy in the validation cohort. The sensitivity and specificity were 73.7 and 78.7%, respectively. The 1- and 2-year cumulative BM rates were 10.8% and 27.4% in the high-risk group and 2.4 and 4.3% in the low-risk group. AUROC The hazard ratio for BM of the high versus low-risk group was (95% CI: ). Conclusion: The simple prediction model constructed from clinicopathological parameters is accurate in predicting BM development in HCC patients. Xiang ZL et al, J Cancer Res Clin Oncol 2011
22 Model for Preoperative Estimation of MVI: Nomogram in HBV related HCC within Milan Criteria N=1004 Patients who had a nomogram score of less than 200 or 200 or greater were considered to have low or high risks of MVI presence, respectively. Conclusions: The nomogram achieved an optimal preoperative prediction of MVI in HBV-related HCC within the Milan criteria. Using the model, the risk for an individual patient to harbor MVI can be determined, which can lead to a rational therapeutic choice Lei Z, Feng Shen et al, JAMA Surg 2015
23 Gene Expression Profiling for Prediction of Ds-free Survival N=286 & 83 Good survival vs Poor survival The estimated 5-year DFS rate for poor-survival patients (n = 41) was 24.1 %compared to 55.3 % for good survival patients (n = 42) (hazard ratio for DFS = 2.375, 95 %confidence interval ). Good survival Poor survival Stage I Stage II/III Stage I Stage II/III DFS rates 59.1% 52.4% 46.2% 12.3% Multivariate analysis in the validation set showed that DFS gene signature of tumor was an Independent predictor of shorter DFS (P = 0.018). Lim HY, Park CK et al, Ann Surg Oncol 2013
24 Predicting Risk of HCC Recurrence : Thrombocytopenia for prediction of HCC recurrence a cutoff value of /L for PLT N=4163 HR = 1.42, 95%CI: In conclusion, our meta-analysis suggested that thrombocytopenia was a valuable, inexpensive predictor for recurrence in patients with HCC. Pang Q et al, World J Gastroenterol 2015;21(25):
25 Score Model for Recurrence after Resection or LT: A 3-factor preoperative scoring model predict risk of recurrence Recurrence risk score model was as follows: HBsAg status (negative: 0; positive: 1) plasma fibrinogen level ( 3.24 mg/dl: 0; >3.24 mg/dl: 1) TTV ( cm3: 0; >107.5 cm3: 1). TTV: total tumor volume. N=238 AUROC The cut-off value was set to 1.02, and we defined the patients with the score 1.02 as a low risk group and those with the score >1.02 as a high risk group. The 3-year recurrence-free survival rate was significantly higher in the low risk group compared with that in the high risk group (67.9% vs 41.3%, P<0.001) Recurrence risk scoring model is effective in categorizing recurrence risks and in predicting recurrence-free survival of HCC before potential surgical curative treatment. Wang LY, Jiang Nan et al, HBPD Int 2015
26 Genomic Predictor Model for Recurrence of HCC: N=72 In multivariate analysis, the 65-gene risk score was the strongest risk factor for very early recurrence (1 y after surgical resection) (hazard ratio, 1.7; 95% confidence interval, ; p= 0.01). The potential significance of STAT3 activation in late recurrence was predicted by gene network analysis and validated later. We also developed and validated 4- and 20-gene predictors from the full 233-gene predictor. Conclusions: Two independently developed predictors reflected well the differences between early and late recurrence of HCC at the molecular level and provided new biomarkers for risk stratification. Kim JH et al, PLoS Med 2014
27 결론 대부분의간세포암예측모델은치료전초기검사를기반으로하고있으며, 치료후적용하기에는비교적제한적이다. 간세포암, 특이진행된간세포암의임상경과에서치료법및치료결과가환자 의생존에미치는영향이지대하므로치료후인자를통한예측모델이더욱 요구된다.
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationJong Young Choi, M.D.
The Liver Week 2014 Jong Young Choi, M.D. Dept. of Internal Medicine The Catholic University of Korea, College of Medicine The clinical study for natural history of LC is not many. Most of them was done
More informationTitle:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis
Author's response to reviews Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis Authors: Mei-Yin Zhang (zhangmy@sysucc.org.cn) Shu-Hong
More information21/02/2014. Disclosures. HCC: predicting recurrence. Outline. Liver transplant: Beyond Milan?
Disclosures HCC: predicting recurrence Peter Ghali, MD, FRCPC, MSc (epid) None relevant to this talk other than off-label use of sirolimus Toronto, February 2014 Outline Recurrence after what? Locoregional
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationWhat have we learned from HBV clinical cohorts?
PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationAntiviral Therapy and Liver Cancer
Antiviral Therapy and Liver Cancer St. Petersburg, 070613 Markus Peck-Radosavljevic Gastroenterologie & Hepatologie AKH & Medizinische Universität Wien HCC Study Group Medizinische Universität Wien Prevention
More informationSerum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope
More informationAdvances in percutaneous ablation for hepatocellular carcinoma
Advances in percutaneous ablation for hepatocellular carcinoma P. Nahon1,2,3 1 Hepatology, Jean Verdier Hospital, APHP, Bondy, France 2 Paris 13 university, Sorbonne Paris Cité, UFRSMBH, Bobigny, France
More informationCIRROSI E IPERTENSIONE PORTALE NELLA DONNA
Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di
More informationNomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
doi: 10.2169/internalmedicine.9064-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation
More informationEffect of hepatitis B virus DNA replication level and anti-hbv therapy on microvascular invasion of hepatocellular carcinoma
Qu et al. Infectious Agents and Cancer (2019) 14:2 https://doi.org/10.1186/s13027-019-0219-8 RESEARCH ARTICLE Open Access Effect of hepatitis B virus DNA replication level and anti-hbv therapy on microvascular
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationWhite Nights of Hepatology 2016
White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationThe Impact of DAA on HCC Occurrence
The Impact of DAA on HCC Occurrence Professeur Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital Paul Brousse Université Paris
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:989 994 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Level of -Fetoprotein Predicts Mortality Among Patients With Hepatitis C Related Hepatocellular
More informationMolecular signature for management of hepatocellular carcinoma
Molecular signature for management of hepatocellular carcinoma Yujin Hoshida, MD, PhD Liver Cancer Program, Tisch Cancer Institute Division of Liver Diseases, Department of Medicine Icahn School of Medicine
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationRisk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화
Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk factors for HCC development (I) Environmental factors Infectious HBV HCV HDV Alimentary Alcohol Diet High
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationNew Tools for Assessing Disease Sererity, progression and regression in HBV and HCV
New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV Jidong Jia, MD, PhD Beijing Friendship Hospital, Capital Medical University 2016-3-14 Disclosure Consultation for Abbvie
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More information간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung
간암의다양한병기분류법 : 현재사용중인병기분류를중심으로 Kim, Beom Kyung Importance of staging system 환자의예후예측 적절한치료방법적용 ( 수술, 방사선, 항암..) 의료진간의 tumor burden 에대한적절한의사소통 향후연구및 clinical trial 시연구집단의성격에대한객관적기준제시 Requisites for good staging
More informationDetection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection
Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1, Nikolaos K. Gatselis 1, Kalliopi Azariadi
More informationSupplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a
Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationStaging and prognostic systems: beyond BCLC?
Staging and prognostic systems: beyond BCLC? Alessandro Vitale, MD, PhD, FEBS U.O.C. di Chirurgia Epatobiliare e dei Trapianti Epatici, Department of Surgery, Oncology and Gastroenterology, University
More informationB C Outlines. Child-Pugh scores
B C 2016-12-09 Outlines Child-Pugh scores CT MRI Fibroscan / ARFI Histologic Scoring Systems for Fibrosis Fibrosis METAVIR Ishak None 0 0 Portal fibrosis (some) 1 1 Portal fibrosis (most) 1 2 Bridging
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationAlpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer. Original Policy Date
MP 2.04.35 Alpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationResearch Article HbA1c-Based Score Model for Predicting Death Risk in Patients with Hepatocellular Carcinoma and Type 2 Diabetes Mellitus
Hindawi Diabetes Research Volume 217, Article ID 381952, 7 pages https://doi.org/1.1155/217/381952 Research Article HbA1c-Based Score Model for Predicting Death Risk in Patients with Hepatocellular Carcinoma
More informationExpression of lncrna TCONS_ in hepatocellular carcinoma and its influence on prognosis and survival
European Review for Medical and Pharmacological Sciences 2017; 21: 5655-5660 Expression of lncrna TCONS_00027978 in hepatocellular carcinoma and its influence on prognosis and survival Q. CHEN 1, G.-D.
More informationDiscontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection
Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Dr Abid Suddle Institute of Liver Studies King s College Hospital Why consider discontinuation of NA therapy?
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationPeri-Transplant Change in AFP Level: A Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation
ORIGINAL ARTICLE Cell Therapy & Organ Transplantation http://dx.doi.org/1.3346/jkms.16.31.7.149 J Korean Med Sci 16; 31: 149-154 Peri-Transplant Change in AFP Level: A Useful Predictor of Hepatocellular
More informationTransient elastography in chronic viral liver diseases
4 th AISF POST-MEETING COURSE Roma, 26 Febbraio 2011 Transient elastography in chronic viral liver diseases CRISTINA RIGAMONTI, M.D., Ph.D. Transient elastography (TE): a rapid, non-invasive technique
More informationAbility of the ALBI grade to predict posthepatectomy liver failure and longterm survival after liver resection for different BCLC stages of HCC
Zhang et al. World Journal of Surgical Oncology (2018) 16:208 https://doi.org/10.1186/s12957-018-1500-9 RESEARCH Open Access Ability of the ALBI grade to predict posthepatectomy liver failure and longterm
More informationAASLD Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital
AASLD 2017 - Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital THE CHANGING LANDSCAPE IN THE TREATMENT OF HCC DISCLAIMER Please note:
More informationONCOLOGY REPORTS 30: 91-98, 2013
ONCOLOGY REPORTS 30: 91-98, 2013 Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma HIROKI
More informationMeasuring levels of osteopontin as potential biomarker for hepatocellular carcinoma in Syrian patients
Gastroenterology and Hepatology From Bed to Bench. 2017 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE Measuring levels of osteopontin as potential biomarker for hepatocellular
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationSERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES
SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES YEON SEOK SEO, 1 SOO YOUNG PARK, 2 MOON YOUNG KIM, 3 SANG GYUNE KIM, 4 JUN YONG PARK, 5 HYUNG JOON YIM,
More informationSIRTEX Lunch Symposium, Cebu, 23 Nov Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong
SIRTEX Lunch Symposium, Cebu, 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong I will not talk on Mechanism of SIRT Data on efficacy of SIRT Epidemiology
More informationHIV and Hepatocellular Carcinoma. Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Rome May 2013
HIV and Hepatocellular Carcinoma Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Rome May 2013 1 In theory, there is no difference between theory and practice In practice there is Chuck
More informationNexavar in advanced HCC: a paradigm shift in clinical practice
Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis
More informationThe Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study
The Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study DK Li, YJ Ren, DS Fierer, S Rutledge, OS Shaikh, V Lo
More informationHepatocellular Carcinoma in Qatar
Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study
More informationCurrent Status of HBV and Liver Transplant
Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationQuantitative Assessment of the Liver: Breath Tests. M. Shadab Siddiqui, M.D. Virginia Commonwealth University
Quantitative Assessment of the Liver: Breath Tests M. Shadab Siddiqui, M.D. Virginia Commonwealth University Objectives Principles of breath tests Breath tests in NAFLD Potential applications of breath
More informationClinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization
ORIGINAL ARTICLE 2018 Oct 26. [Epub ahead of print] https://doi.org/10.3904/kjim.2018.058 Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial
More information«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients
«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients Δημήτρησ Ν. αμωνάκησ Γαςτρεντερολογική κλινική Πανεπιςτημίου Κρήτησ Outline Epidemiology Risk factors
More informationBackground. ΝΑ therapy in CHBe- until HBsAg clearance. (EASL guidelines 2012)
Interferon-induced protein 10 (IP10) at discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy cannot predict subsequent relapses in non-cirrhotic HBeAgnegative chronic hepatitis B (CHBe-)
More informationAddictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis
Addictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis Gwang Hyeon Choi, Ju Hyun Shim*, Min-Joo Kim, Min-Hee Ryu, Baek-Yeol
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationPreoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis
3862 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(18): 3862-3867. doi: 10.7150/jca.21313 Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationSi Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong Jun Song, 1,4 Woo Jin Chung, 1,5
Comparison of efficacy between hepatic arterial infusion chemotherapy and sorafenib in advanced hepatocellular carcinoma with portal vein tumor thrombosis 1,2,3 Si Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong
More informationThe Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis
pissn 1598-2998, eissn 25-9256 Original Article http://dx.doi.org/1143/crt.215.32 Open Access The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis Sang Yun Ha, MD, PhD
More informationALPHA-FETOPROTEIN-L3 FOR DETECTION OF HEPATOCELLULAR CANCER
Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon
More informationDiabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v22.i43.9571 World J Gastroenterol 2016 November 21; 22(43): 9571-9585 ISSN 1007-9327
More informationAmmonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis
Gastroenterology Report, 5(3), 2017, 232 236 doi: 10.1093/gastro/gow010 Advance Access Publication Date: 1 May 2016 Original article ORIGINAL ARTICLE Ammonia level at admission predicts in-hospital mortality
More informationManagement of hepatocellular carcinoma should consider both tumor factors and background liver factors
Hepatocellular Carcinoma Column: Editorial Management of hepatocellular carcinoma should consider both tumor factors and background liver factors Shuji Nomoto, Mitsuhiro Hishida, Yoshikuni Inokawa, Hiroyuki
More informationAASLD Immune tolerant phase HBV NAFLD diagnostic HCC
AASLD 2016 Immune tolerant phase HBV NAFLD diagnostic HCC Immune tolerant 3 Modified from Chan HLY and Wong VWS. Hepatitis B. In Zakim and Boyers s Hepatology 2012 2015 AMERICAN ASSOCIATION FOR THE S1T6UDY
More informationHepatocellular carcinoma (HCC) is the sixth most common type of cancer and ranks
Diagn Interv Radiol 2018; 24:121 127 Turkish Society of Radiology 2018 ABDOMINAL IMAGING ORIGINAL ARTICLE A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B
More informationDuring the past 2 decades, an increase in the ageadjusted
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:104 110 Racial Differences in Survival of Hepatocellular Carcinoma in the United States: A Population-Based Study JESSICA A. DAVILA* and HASHEM B. EL SERAG*,
More informationAnalysis of prognostic factors of more/equal to10 years of survival for liver cancer patients after liver transplantation
Journal of Cancer Research and Clinical Oncology (2018) 144:2465 2474 https://doi.org/10.1007/s00432-018-2756-8 ORIGINAL ARTICLE CLINICAL ONCOLOGY Analysis of prognostic factors of more/equal to10 years
More informationTreatment of HCC in real life-chinese perspective
Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA
More informationHepatitis B virus (HBV) infection is a global
VIRAL HEPATITIS Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Tai-Chung Tseng, 1,3,8 Chun-Jen Liu, 2,3 Hung-Chih Yang, 2,6 Tung-Hung
More informationClinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan
Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan Why is staging system important? Cancer stage can be
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More information